Reduction in D-dimer levels after treatment with Auxora in patients with severe COVID-19 pneumonia

Reduction in D-dimer levels after treatment with Auxora in patients with severe COVID-19 pneumonia

Introduction: A phase 2 double-blinded trial (CARDEA) (NCT04345614) in patients diagnosed with COVID-19 revealed that intravenous zegocractin treatment (Auxora™) was associated with improved clinical outcomes compared to standard of care (SOC). D-dimer serum level is a biomarker of thrombosis in COV...

Full description

Saved in:
Bibliographic Details
Main Authors: Peter C. Hou, Joseph Miller, Charles Bruen, Fady Youssef, Michael J. Schnaus, Kathyrn Brouillette, Raul Mendoza-Ayala, Jeffrey Zhang, Kenneth Stauderman, Sudarshan Hebbar
Format: Article
Language:English
Published: Elsevier 2025-09-01
Series:Thrombosis Update
Subjects:
Auxora
Calcium release-activated channel (CRAC) inhibitor
Severe COVID-19 pneumonia
D-dimer
Biomarkers
Online Access:http://www.sciencedirect.com/science/article/pii/S2666572725000203
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

http://www.sciencedirect.com/science/article/pii/S2666572725000203

Similar Items